S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.30 (+1.32%)
AAPL   435.00 (+2.34%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.90 (-0.34%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.12 (+4.60%)
BABA   258.00 (+2.78%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.66 (+0.30%)
T   29.60 (+0.07%)
F   6.69 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.50 (+2.83%)
NFLX   498.62 (+1.99%)
DIS   116.23 (-0.61%)
BAC   24.98 (+0.40%)
BA   162.00 (+2.53%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.30 (+1.32%)
AAPL   435.00 (+2.34%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.90 (-0.34%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.12 (+4.60%)
BABA   258.00 (+2.78%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.66 (+0.30%)
T   29.60 (+0.07%)
F   6.69 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.50 (+2.83%)
NFLX   498.62 (+1.99%)
DIS   116.23 (-0.61%)
BAC   24.98 (+0.40%)
BA   162.00 (+2.53%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.30 (+1.32%)
AAPL   435.00 (+2.34%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.90 (-0.34%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.12 (+4.60%)
BABA   258.00 (+2.78%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.66 (+0.30%)
T   29.60 (+0.07%)
F   6.69 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.50 (+2.83%)
NFLX   498.62 (+1.99%)
DIS   116.23 (-0.61%)
BAC   24.98 (+0.40%)
BA   162.00 (+2.53%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.30 (+1.32%)
AAPL   435.00 (+2.34%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.90 (-0.34%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.12 (+4.60%)
BABA   258.00 (+2.78%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.66 (+0.30%)
T   29.60 (+0.07%)
F   6.69 (+1.21%)
ACB   10.43 (+2.36%)
GILD   71.50 (+2.83%)
NFLX   498.62 (+1.99%)
DIS   116.23 (-0.61%)
BAC   24.98 (+0.40%)
BA   162.00 (+2.53%)
Log in

NYSE:RDYDr.Reddy's Laboratories Stock Price, Forecast & News

$60.12
-0.68 (-1.12 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$59.75
Now: $60.12
$60.85
50-Day Range
$51.39
MA: $53.41
$59.92
52-Week Range
$33.33
Now: $60.12
$60.95
Volume7,382 shs
Average Volume178,328 shs
Market Capitalization$9.96 billion
P/E Ratio39.55
Dividend Yield0.45%
Beta0.52
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Read More
Dr.Reddy

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone91-40-4900-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.32 billion
Cash Flow$3.75 per share
Book Value$12.41 per share

Profitability

Net Income$259 million

Miscellaneous

Employees21,650
Market Cap$9.96 billion
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$60.12
-0.68 (-1.12 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

How has Dr.Reddy's Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Dr.Reddy's Laboratories' stock was trading at $40.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RDY shares have increased by 49.7% and is now trading at $60.12.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Dr.Reddy's Laboratories?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr.Reddy's Laboratories in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Dr.Reddy's Laboratories
.

When is Dr.Reddy's Laboratories' next earnings date?

Dr.Reddy's Laboratories is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Dr.Reddy's Laboratories
.

How were Dr.Reddy's Laboratories' earnings last quarter?

Dr.Reddy's Laboratories Ltd (NYSE:RDY) announced its earnings results on Wednesday, July, 29th. The company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.42 by $0.04. The firm earned $585 million during the quarter. Dr.Reddy's Laboratories had a return on equity of 18.88% and a net margin of 10.26%.
View Dr.Reddy's Laboratories' earnings history
.

How often does Dr.Reddy's Laboratories pay dividends? What is the dividend yield for Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories announced an annual dividend on Thursday, July 9th. Shareholders of record on Friday, January 1st will be paid a dividend of $0.3304 per share on Friday, July 10th. This represents a yield of 0.5%. The ex-dividend date is Friday, July 10th. This is an increase from Dr.Reddy's Laboratories's previous annual dividend of $0.27.
View Dr.Reddy's Laboratories' dividend history
.

What price target have analysts set for RDY?

5 brokers have issued 12-month price targets for Dr.Reddy's Laboratories' stock. Their forecasts range from $53.00 to $53.00. On average, they anticipate Dr.Reddy's Laboratories' share price to reach $53.00 in the next twelve months. This suggests that the stock has a possible downside of 11.8%.
View analysts' price targets for Dr.Reddy's Laboratories
.

Has Dr.Reddy's Laboratories been receiving favorable news coverage?

News coverage about RDY stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dr.Reddy's Laboratories earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Dr.Reddy's Laboratories
.

Who are some of Dr.Reddy's Laboratories' key competitors?

What other stocks do shareholders of Dr.Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr.Reddy's Laboratories investors own include Siemens (SIEGY), Tata Motors (TTM), Infosys (INFY), Vedanta (VEDL), HDFC Bank (HDB), Alibaba Group (BABA), GlaxoSmithKline (GSK), Merck & Co., Inc. (MRK), Gilead Sciences (GILD) and ICICI Bank (IBN).

Who are Dr.Reddy's Laboratories' key executives?

Dr.Reddy's Laboratories' management team includes the following people:
  • Mr. Gunupati Venkateswara Prasad, Co-Chairman, MD, CEO & Member of Management Council (Age 59)
  • Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 52)
  • Mr. Saumen Chakraborty, Pres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt Council (Age 58)
  • Mr. M. V. Ramana, CEO & Head of Branded Markets - India & Emerging Countries and Member of Management Council (Age 50)
  • Mr. Ganadhish Kamat, Exec. VP, Global Head of Quality & Member of Management Council (Age 56)

What is Dr.Reddy's Laboratories' stock symbol?

Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

Who are Dr.Reddy's Laboratories' major shareholders?

Dr.Reddy's Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional investors include Strs Ohio (0.12%), First Trust Advisors LP (0.08%), Dorsey Wright & Associates (0.04%), UBS Group AG (0.02%), Portland Hill Asset Management Ltd (0.02%) and Henry James International Management Inc. (0.01%).

Which major investors are selling Dr.Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, UBS Group AG, Dorsey Wright & Associates, JustInvest LLC, Parallel Advisors LLC, Hanson & Doremus Investment Management, Henry James International Management Inc., and Creative Planning.

Which major investors are buying Dr.Reddy's Laboratories stock?

RDY stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Ritholtz Wealth Management, Brinker Capital Inc., Confluence Investment Management LLC, First Trust Advisors LP, Personal CFO Solutions LLC, Campbell & CO Investment Adviser LLC, and Fulton Bank N. A..

How do I buy shares of Dr.Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dr.Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $60.12.

How big of a company is Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories has a market capitalization of $9.96 billion and generates $2.32 billion in revenue each year. The company earns $259 million in net income (profit) each year or $2.79 on an earnings per share basis. Dr.Reddy's Laboratories employs 21,650 workers across the globe.

What is Dr.Reddy's Laboratories' official website?

The official website for Dr.Reddy's Laboratories is www.drreddys.com.

How can I contact Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.